Basosquamous Carcinoma: Symptoms, Causes, and Treatment

Basosquamous carcinoma is a relatively uncommon skin cancer that blends features of basal cell carcinoma and squamous cell carcinoma into a single tumor, and it tends to behave more aggressively than either parent type on its own. Often abbreviated BSC, it carries an estimated metastatic potential of roughly 5 to 10 percent, which is dramatically higher than ordinary basal cell carcinoma’s rate of well under 1 percent.¹ Because BSC looks almost identical to a common basal cell carcinoma on the surface of the skin, the diagnosis is frequently missed until a biopsy reveals the mixed pattern under a microscope.

What BSC Looks Like on the Skin

The frustrating reality about basosquamous carcinoma is that it does not announce itself with any distinctive visual signature. Its clinical appearance is essentially the same as an ordinary basal cell carcinoma: a slow-growing bump, often skin-colored or slightly pink, that may develop a pearly or translucent border. The most common scenario is a nodule that has been present for a long time and gradually becomes ulcerated, sometimes crusting over and bleeding before partially healing again.²

The head and neck account for the vast majority of cases, with between 75 and 97 percent of tumors appearing in sun-exposed areas of the face, particularly around the nose and ears.² That said, BSC also turns up on the trunk and extremities. In one large cohort, the mean age at diagnosis was about 75 years, and men were affected roughly 1.6 times as often as women.³ Because BSC can mimic so many other lesions, you should not expect to identify it by sight alone. Any non-healing sore, slowly enlarging bump, or persistently crusted patch on sun-exposed skin warrants a visit to a dermatologist.

Causes and Risk Factors

Cumulative sun exposure is the dominant risk factor. In one study examining BSC alongside squamous cell carcinoma, about 80 percent of patients reported high lifetime sun exposure.⁴ The mechanism is the same as for other nonmelanoma skin cancers: ultraviolet radiation damages DNA in skin cells over decades, eventually accumulating enough mutations to trigger uncontrolled growth.

At the genetic level, BSC appears to begin as a basal cell carcinoma and then acquire additional mutations that push part of the tumor toward squamous cell behavior. Researchers have found that BSC tumors frequently carry mutations in the Hedgehog signaling pathway, the same pathway disrupted in ordinary basal cell carcinoma, suggesting that Hedgehog deregulation is the primary initiating event. What makes BSC different is what happens next: about 45 percent of tumors also carry mutations in a gene called ARID1A, and these mutations seem to occur after the initial Hedgehog disruption but before the squamous features develop. This sequence suggests that ARID1A mutations give the tumor a kind of plasticity, enabling the shift from purely basal to mixed basal-squamous character.⁵

People whose immune systems are suppressed face elevated skin cancer risk across the board, and BSC is no exception. A study of over 3,500 organ transplant recipients found that BSC developed on average about 13 years after transplantation, somewhat later than other skin cancers. The transplant recipients who developed BSC tended to be younger than non-transplant patients with BSC, and their tumors were thinner. However, they went on to develop strikingly large numbers of additional skin lesions during follow-up, with some patients accumulating over 200 premalignant and malignant skin tumors over time.⁶

How BSC Is Diagnosed

Because basosquamous carcinoma looks so much like ordinary basal cell carcinoma on the surface, a definitive diagnosis requires a tissue biopsy examined under the microscope. The hallmark is the presence of three distinct zones within the same tumor: a region of basaloid cells typical of BCC, a region of squamous cells typical of SCC, and a transition zone between them where the cell type gradually shifts.⁷ This three-zone architecture is what separates BSC from a BCC that merely has a few squamous-looking cells scattered through it.

Special staining helps confirm the diagnosis. A marker called Ber-EP4 lights up strongly in basal cell carcinomas but not in squamous cell carcinomas. In BSC, you see strong Ber-EP4 staining in the BCC portion that gradually fades as you move through the transition zone into the squamous area.⁸ Another marker, epithelial membrane antigen, shows the opposite pattern, staining the squamous portion but not the basal portion. These complementary staining patterns are useful when the biopsy is ambiguous.

Dermoscopy as a Screening Clue

Before a biopsy is taken, dermatologists often examine a lesion with a dermatoscope, a handheld device that provides magnified, illuminated views of the skin surface. BSC has a recognizable dermoscopic signature for clinicians who know to look for it: it combines vascular features typical of BCC with surface features typical of SCC. Almost all BSC tumors show at least one BCC-related feature alongside at least one SCC-related feature.⁹

Specifically, keratin masses and surface scaling were among the most commonly seen features, appearing in over 70 percent of BSC lesions, alongside branching blood vessels more typical of BCC. White circles, a finding usually associated with squamous cell carcinoma, also appeared in BSC at similar rates.¹⁰ In practice, if a dermatologist sees a lesion that appears to be a BCC but has unexpected scaling or keratinization, that mismatch should raise suspicion for BSC and prompt a deeper biopsy.

The Confusion Between BCC and SCC

BSC is not the only lesion that blurs the line between basal and squamous cell carcinoma. Even straightforward BCCs and SCCs are sometimes confused with each other clinically. Scales on the surface tend to point toward SCC, while pigmentation and a rolled border favor BCC. Features like ulceration and visible blood vessels, which many people associate exclusively with BCC, actually appear in both types and contribute to misdiagnosis.¹¹ BSC sits right in this diagnostic gray zone, which is one reason it is often not recognized until pathology results come back.

Surgical Treatment

Surgery is the primary treatment for BSC, and the type of surgery matters. Standard excision with a margin of healthy tissue around the tumor is the most widely used approach. A multicenter study found that surgeons typically aim for peripheral margins of about 4 millimeters, but inadequate excision, where the tumor reaches the edge of the removed tissue, occurred in roughly a quarter of cases.¹ Inadequate margins were most common on the face, where surgeons must balance complete tumor removal against cosmetic and functional concerns. When margins are positive, re-excision or adjuvant radiotherapy is typically recommended.

Mohs micrographic surgery, a technique where tissue is removed in thin layers and examined under the microscope in real time until no tumor cells remain at the edges, has produced strong results. In one study of patients treated with Mohs surgery and followed for at least five years, only about 4 percent experienced recurrence.¹² That is a significant improvement over standard excision, where recurrence rates for BSC are generally higher. Even so, BSC retains a reputation for aggressiveness, and some tumors do recur even after apparently complete Mohs clearance.¹³

Sentinel Lymph Node Biopsy

Because BSC carries a meaningful risk of spreading to lymph nodes, sentinel lymph node biopsy has been explored as a staging tool, particularly for larger or higher-risk tumors. In a cross-sectional study, sentinel lymph node metastasis rates varied sharply by tumor size: under 1 percent for tumors 2 centimeters or smaller, about 12 percent for tumors between 2 and 3 centimeters, and 80 percent for tumors larger than 3 centimeters. Perineural invasion and lymphatic invasion were both strongly associated with positive sentinel nodes.¹⁴

This steep size gradient has practical implications. For small BSC tumors treated with adequate margins, sentinel lymph node biopsy adds little value and is generally not recommended. But for larger tumors, particularly those over 3 centimeters or those with perineural invasion, several groups have argued that sentinel lymph node biopsy should be considered even when no lymph nodes are palpable on examination.¹⁵ Case reports have documented metastatic BSC detected by sentinel node biopsy in patients who would otherwise have been assumed to be disease-free.¹⁶

Targeted Therapy and Immunotherapy

When BSC is locally advanced or metastatic and surgery is not feasible, systemic drug treatments enter the picture. Because BSC originates through Hedgehog pathway mutations, drugs that block that pathway, called Hedgehog pathway inhibitors, are a logical first-line option. Preliminary data suggest that sonidegib and vismodegib can be safe and effective initial treatments for BSC, with the anti-PD-1 immunotherapy drug cemiplimab serving as a useful second-line choice if the Hedgehog inhibitors fail or are not tolerated.¹⁷

Combined approaches have also shown promise in individual cases. One published case report described a patient with a large BSC who achieved complete remission after treatment with both cemiplimab and vismodegib, remaining disease-free through 31 treatment cycles.¹⁸ It is worth noting that the evidence base here consists largely of case series and small studies rather than large randomized trials. BSC is rare enough that assembling big trial populations is genuinely difficult, so clinicians often extrapolate from the larger BCC and SCC literature while watching for BSC-specific data as it accumulates.

Hedgehog inhibitors come with real side effects. Muscle spasms, hair loss, taste disturbances, and fatigue are common complaints. In a multicenter Italian study of advanced BCC patients treated with vismodegib or sonidegib, nearly half of vismodegib patients discontinued treatment because of side effects, compared with about 13 percent of those on sonidegib.¹⁹ These tolerability differences may influence which drug a clinician tries first, although individual responses vary.

What Influences Prognosis

Several factors determine how a given BSC tumor is likely to behave. Tumor depth and size are the most consistent predictors. In a study of head and neck BSC, deeper tumors and those with a higher T classification were significantly associated with local recurrence, lymph node metastasis, and shorter progression-free survival. Location mattered too: tumors on the ear carried a worse prognosis than those in other head and neck sites. Incomplete resection and invasion into muscle or blood vessels also predicted worse outcomes.²⁰

The picture is not universally grim, though. The evidence is somewhat contradictory on how aggressive BSC truly is in practice. One single-center study of 74 patients found zero cases of local recurrence or metastasis when tumors were adequately excised, leading the authors to conclude that their cohort appeared less aggressive than previously described.³ Similarly, the multicenter study found that patients with smaller tumors (pT1 and pT2) who underwent primary excision had excellent outcomes with no recurrence or metastasis during follow-up.¹ The lesson seems to be that BSC’s reputation for aggressiveness is driven largely by a subset of advanced, deeply invasive, or incompletely excised tumors. Caught small and removed with clear margins, many BSCs behave quite well.

Follow-Up After Treatment

The World Health Organization’s classification of skin tumors places BSC among the high-risk subtypes of basal cell carcinoma, alongside infiltrating, sclerosing, and micronodular variants.²¹ That classification has practical consequences for how closely patients are monitored after treatment. Guidelines generally call for more frequent skin checks in the years following BSC removal than after an ordinary nodular BCC. Clinical practice varies by institution, but follow-up intervals of every three to six months for the first two years, then annually for several more years, are common for high-risk subtypes.

Patients who have had one BSC are also at elevated risk for additional skin cancers, particularly if they carry the underlying risk factors of fair skin and extensive sun exposure. Self-examination of the skin between clinic visits is a practical step that can catch new lesions early. Any new bump, non-healing sore, or changing lesion in a patient with a BSC history should prompt a visit rather than a wait-and-see approach.

Why BSC Is Frequently Misclassified Initially

A recurring theme in the BSC literature is that the tumor is often not diagnosed correctly on the initial biopsy. One reason is sampling error. A small punch biopsy may capture only the basal cell portion of the tumor, missing the squamous component entirely and returning a diagnosis of ordinary BCC. The three-zone architecture that defines BSC may only become apparent when the full tumor is excised and examined. This is why some BSC diagnoses arrive as a surprise on the final pathology report after what was supposed to be routine BCC surgery.

Another complication is that pathologists themselves sometimes disagree about where to draw the line between a BCC with squamous differentiation and a true basosquamous carcinoma. The distinction matters clinically because BSC carries higher recurrence and metastatic rates, but the histologic boundary between the two is not always crisp. Immunohistochemical staining helps, as discussed earlier, but there is no single definitive marker for BSC. The gradual decline of Ber-EP4 staining across the transition zone is the closest thing to a signature finding.⁷

For patients, the practical takeaway is straightforward: if your pathology report comes back showing basosquamous carcinoma, the treatment plan should reflect its higher-risk status compared to ordinary BCC, even if the tumor looks small and unremarkable on the surface. Wider surgical margins, consideration of Mohs surgery, and a more vigilant follow-up schedule are all appropriate responses. Conversely, if you have been diagnosed with a BCC that recurs unexpectedly or behaves more aggressively than expected, it is reasonable to ask whether re-examination of the tissue might reveal basosquamous features that were initially missed.

Organ Transplant Recipients and Immunosuppressed Patients

People taking immunosuppressive medications after organ transplantation develop nonmelanoma skin cancers at dramatically higher rates than the general population. BSC is no exception, though it follows a slightly different pattern. In the large transplant cohort mentioned earlier, BSC appeared later after transplantation than other skin cancers, with a mean delay of about 13 years from the time of the graft. The tumors themselves were thinner and occurred in younger patients compared to BSC in the general population. During follow-up, none of the transplant patients in that study developed metastases from their BSC.⁶

The more pressing concern for transplant recipients is the sheer volume of skin cancers that follow. Patients who developed BSC went on to accumulate enormous numbers of additional premalignant and malignant skin lesions, sometimes well over a hundred. For this population, the management challenge is less about any individual BSC and more about the relentless accumulation of skin cancers that require ongoing surveillance, repeated procedures, and careful coordination between dermatology and transplant teams. Dermatologists who manage transplant patients typically see them at very short intervals, sometimes every few months indefinitely, and have a low threshold for biopsying anything that looks suspicious.